Shilpa Medicare has received GMP certification from Saudi Food and Drug Authority (SFDA), Saudi Arabia, for its Unit VI facility, located at Dabaspet, Bengaluru. This follows the on-site inspection of this site from February 18 to February 20, 2025, which was closed with ZERO observations. This was a full GMP inspection of entire facility with specific focus on Ondansetron Oral Film drug product.
This facility of the company is engaged in the manufacture, testing, storage and release of finished dosage forms in the category of Oral Films and Transdermal Patches. Oral Films are currently being supplied from this site to US, Australia and other Emerging countries. The site is approved by European Medicine Agency, Europe following a recent inspection by Finnish regulators.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
